In recent days, Boston Scientific has drawn upbeat commentary from Wall Street, with analysts citing strong demand across ...
We definitely have an attention problem, but it’s not just a function of the digital technology that pings and beeps and ...
Structural heart news arrived in a steady stream throughout 2025—from pivotal trials to approvals, reimbursement decisions, ...
Medical Device Network on MSN
Gore acquires Conformal Medical to broaden endovascular portfolio
W. L. Gore & Associates (Gore) has acquired Conformal Medical in bid to strengthen the US multinational’s endovascular ...
Cardiac Electrophysiology Institute Expands Catheter Ablation Access For Los Angeles Heart Rhythm Patients. <a href = target= ...
SAN FRANCISCO -- Two mainstream devices for percutaneous left atrial appendage (LAA) closure continued to lead to similar clinical outcomes in the SWISS-APERO trial. Among patients randomized to the ...
A steady stream of structural trial data, approvals, reimbursement decisions, and real-world rollouts arrived in 2025.
W.L. Gore & Associates announced today that it agreed to acquire left atrial appendage occlusion (LAAO) device maker ...
Boston Scientific Corporation is rated a Hold with double-digit revenue growth and margin expansion. Learn more about BSX stock here.
Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.
SHORT STORIES/ESSAYS The Land of Sweet Forever Harper Lee Penguin, $49.99. When Harper Lee published To Kill a Mockingbird in ...
Boston Scientific is a Buy with a $109 target and 14% upside from strong demand, Q3 beats, raised FY25 guidance, and growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback